<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d171">
    <sentence id="DDI-DrugBank.d171.s0" text="Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.">
        <entity id="DDI-DrugBank.d171.s0.e0" charOffset="0-6"
            type="brand" text="Tagamet"/>
        <entity id="DDI-DrugBank.d171.s0.e1" charOffset="130-157"
            type="group" text="warfarin-type anticoagulants"/>
        <entity id="DDI-DrugBank.d171.s0.e2" charOffset="160-168"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d171.s0.e3" charOffset="171-181"
            type="drug" text="propranolol"/>
        <entity id="DDI-DrugBank.d171.s0.e4" charOffset="184-193"
            type="drug" text="nifedipine"/>
        <entity id="DDI-DrugBank.d171.s0.e5" charOffset="196-211"
            type="drug" text="chlordiazepoxide"/>
        <entity id="DDI-DrugBank.d171.s0.e6" charOffset="214-221"
            type="drug" text="diazepam"/>
        <entity id="DDI-DrugBank.d171.s0.e7" charOffset="232-256"
            type="group" text="tricyclic antidepressants"/>
        <entity id="DDI-DrugBank.d171.s0.e8" charOffset="259-267"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d171.s0.e9" charOffset="270-281"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d171.s0.e10" charOffset="287-299"
            type="drug" text="metronidazole"/>
        <ddi id="DDI-DrugBank.d171.s0.d0" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d1" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e2" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d2" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e3" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d3" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e4" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d4" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e5" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d5" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e6" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d6" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e7" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d7" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e8" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d8" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e9" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s0.d9" e1="DDI-DrugBank.d171.s0.e0"
            e2="DDI-DrugBank.d171.s0.e10" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s1" text="Clinically significant effects have been reported with the warfarin anticoagulants;">
        <entity id="DDI-DrugBank.d171.s1.e0" charOffset="59-81"
            type="group" text="warfarin anticoagulants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s2" text="therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.">
        <entity id="DDI-DrugBank.d171.s2.e0" charOffset="86-98"
            type="group" text="anticoagulant"/>
        <entity id="DDI-DrugBank.d171.s2.e1" charOffset="127-133"
            type="brand" text="Tagamet"/>
        <ddi id="DDI-DrugBank.d171.s2.d0" e1="DDI-DrugBank.d171.s2.e0"
            e2="DDI-DrugBank.d171.s2.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s3" text="Interaction with phenytoin, lidocaine and theophylline has also been reported to produce adverse clinical effects.">
        <entity id="DDI-DrugBank.d171.s3.e0" charOffset="17-25"
            type="drug" text="phenytoin"/>
        <entity id="DDI-DrugBank.d171.s3.e1" charOffset="28-36"
            type="drug" text="lidocaine"/>
        <entity id="DDI-DrugBank.d171.s3.e2" charOffset="42-53"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s4" text="However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.">
        <entity id="DDI-DrugBank.d171.s4.e0" charOffset="64-70"
            type="brand" text="Tagamet"/>
        <entity id="DDI-DrugBank.d171.s4.e1" charOffset="146-157"
            type="drug" text="theophylline"/>
        <entity id="DDI-DrugBank.d171.s4.e2" charOffset="160-167"
            type="brand" text="Theo-Dur"/>
        <entity id="DDI-DrugBank.d171.s4.e3" charOffset="243-254"
            type="drug" text="theophylline"/>
        <ddi id="DDI-DrugBank.d171.s4.d0" e1="DDI-DrugBank.d171.s4.e0"
            e2="DDI-DrugBank.d171.s4.e1" type="mechanism"/>
        <ddi id="DDI-DrugBank.d171.s4.d1" e1="DDI-DrugBank.d171.s4.e0"
            e2="DDI-DrugBank.d171.s4.e2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s5" text="Data beyond 10 days are not available."/>
    <sentence id="DDI-DrugBank.d171.s6" text="(Note: All patients receiving theophylline should be monitored appropriately, regardless of concomitant drug therapy.)">
        <entity id="DDI-DrugBank.d171.s6.e0" charOffset="30-41"
            type="drug" text="theophylline"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s7" text="Dosage of the drugs mentioned above and other similarly metabolized drugs, particularly those of low therapeutic ratio or in patients with renal and/or hepatic impairment, may require adjustment when starting or stopping concomitantly administered Tagamet to maintain optimum therapeutic blood levels.">
        <entity id="DDI-DrugBank.d171.s7.e0" charOffset="248-254"
            type="brand" text="Tagamet"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s8" text="Alteration of pH may affect absorption of certain drugs (e.g., ketoconazole).">
        <entity id="DDI-DrugBank.d171.s8.e0" charOffset="63-74"
            type="drug" text="ketoconazole"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s9" text="If these products are needed, they should be given at least 2 hours before cimetidine administration.">
        <entity id="DDI-DrugBank.d171.s9.e0" charOffset="75-84"
            type="drug" text="cimetidine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d171.s10" text="Additional clinical experience may reveal other drugs affected by the concomitant administration of Tagamet.">
        <entity id="DDI-DrugBank.d171.s10.e0" charOffset="100-106"
            type="brand" text="Tagamet"/>
    </sentence>
</document>
